The cumulative expertise of the Cardinal Partners spans multiple industry sub-sectors. As early/growth-stage investors with deep experience and superior investment returns we have demonstrated that we know how to successfully build durable, valuable companies throughout multiple business and economic cycles.
QPID Artificial Intelligence (AI) software uses NLP and machine learning to generate fact from medical records for CDS, CCM and Quality Reporting. Cardinal Partners was a participant in “spin-out” financing from Partners HealthCare. QPID Health was acquired by eviCore healthcare, a leading medical benefits management company.
Cubist Pharmaceuticals was a U.S. biopharmaceutical company with activities spanning from research and development to commercialization of pharmaceutical products. Its main products target pathogens like MRSA. In 2014, Merck & Co. acquired Cubist for $102 per share in cash ($8.4 billion) as entree to the market for drugs that can combat superbugs.
Web-based physician directory / decision-support tool. The largest online database of patient reviews for doctors and facilities. Sapphire-Digital has developed a SmartShopper tool that helps consumers navigate services with a concierge system to find high quality, lower cost providers. Acquired by Zelis in Sep, 2021.
National (and International) Leader in Telehealth Services: “medicine to the masses”, providing doctor consults to consumers. Speak to a licensed doctor by web, phone or mobile app in minutes. Cardinal Partners is lead investor, raising capital and IPO process, assisting with strategic partnerships and M&A.
Verastem is focusing on a portfolio of small molecule drugs inhibiting critical signaling pathways in cancer, including the phosphoinositide 3-kinase (PI3K) and focal adhesion kinase (FAK) pathways. These signaling pathways are abnormal in cancer and promote tumor survival. Preclinical research has shown these pathways also contribute to the protective nature of the tumor microenvironment, thereby limiting the effectiveness of existing cancer treatments.
Cloud based medical imaging sharing platform for hospitals, physicians and patients. CHP III lead 2nd round financing.Founded in 2008, Life Image has spent the past decade innovating an interoperable network ecosystem that connects hospitals, physicians, patients, life sciences, medical device companies, telehealth companies, and EHRS.
Momenta is a biotechnology company with a validated innovative scientific platform focused on discovering and developing novel therapeutics to treat rare, immune-mediated diseases. Drug discovery based on glycomics, (the study of complex sugars) Groundbreaking application in the area of developing generic biologics. CHP II was founding investor, June 2004 IPO. Co-Investors: Polaris, Atlas, MVM, Mithra.
Novel drug development platform targeting central nervous system diseases. Platform has generated dozens of drug leads with clinical trials underway in Tourette’s Syndrome, MS and Agitation in Alzheimer’s Patients. Cardinal Partners is founding investor. May 2019 – Acquired by Denmark’s H. Lundbeck A/S.
Vividion is a next generation biotechnology company focused on expanding the therapeutic potential of small molecules. Drug development technology platform for a broad array of protein targets that have heretofore been deemed ‘undruggable’. CHP III is founding investor. August 2021 – acquired by Bayer AG for $2 billion.